Department of Molecular and Cellular Biochemistry, University of Kentucky, College of Medicine, Lexington, KY, USA.
University of Kentucky, Markey Cancer Center, Lexington, KY, USA.
FEBS J. 2021 Dec;288(23):6674-6676. doi: 10.1111/febs.16120. Epub 2021 Jul 29.
Over 34 000 patients are diagnosed yearly with multiple myeloma (MM), which remains a fatal malignancy. Expression of the phosphatase PRL-3 is associated with poor prognosis in MM patients, and Vandsemb et al. have demonstrated that PRL-3 contributes to enhanced MM cell fitness through activation of a glycolysis-associated feedback loop. PRL-3 resulted in increased expression of signal transducer and activator of transcription 1 (STAT1) and 2 (STAT2) and increased glycolysis. Increased glucose metabolism in turn activated STAT1/2 and interferon 1-related genes. This discovery advances the MM field by providing a new potential treatment avenue. Comment on: https://doi.org/10.1111/febs.16058.
每年有超过 34000 名患者被诊断患有多发性骨髓瘤 (MM),这仍然是一种致命的恶性肿瘤。磷酸酶 PRL-3 的表达与 MM 患者的预后不良有关,Vandsemb 等人已经证明,PRL-3 通过激活与糖酵解相关的反馈环,促进 MM 细胞的适应性。PRL-3 导致信号转导和转录激活因子 1 (STAT1) 和 2 (STAT2) 的表达增加和糖酵解增加。葡萄糖代谢的增加反过来又激活了 STAT1/2 和干扰素 1 相关基因。这一发现为 MM 领域提供了新的潜在治疗途径,推进了该领域的发展。评论:https://doi.org/10.1111/febs.16058。